GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » Scaled Net Operating Assets

KANT (Kineta) Scaled Net Operating Assets : -3.36 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Kineta Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Kineta's operating assets for the quarter that ended in Jun. 2024 was $0.50 Mil. Kineta's operating liabilities for the quarter that ended in Jun. 2024 was $8.67 Mil. Kineta's Total Assets for the quarter that ended in Mar. 2024 was $2.43 Mil. Therefore, Kineta's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was -3.36.

Kineta Scaled Net Operating Assets Historical Data

The historical data trend for Kineta's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Scaled Net Operating Assets Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
-0.59 -0.10 -0.47 -0.08

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 -0.17 -0.13 -0.67 -3.36

Competitive Comparison of Kineta's Scaled Net Operating Assets

For the Biotechnology subindustry, Kineta's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Kineta's Scaled Net Operating Assets falls into.


Kineta Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Kineta's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(4.498-5.905)/17.435
=-0.08

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.281 - 5.783
=4.498

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.222 - 0.15 - 1.167
=5.905

Kineta's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Mar. 2024 )
=(0.499-8.668)/2.433
=-3.36

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1.399 - 0.9
=0.499

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=9.378 - 0 - 0.71
=8.668

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kineta Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Kineta's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (OTCPK:KANT) » Definitions » Scaled Net Operating Assets
Comparable Companies
GDTC OKYO MTNB SPRB YS DYAI DTIL COYA AGLE IMUX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
J75:Germany
Address
7683 SE 27th Street, Suite 481, Mercer Island, WA, USA, 98040
Website
https://www.kinetabio.com
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Executives
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky director C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust 10 percent owner C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust 10 percent owner C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109